RUNX1 mutations contribute to the progression of MDS due to disruption of antitumor cellular defense...
RUNX1 mutations contribute to the progression of MDS due to disruption of antitumor cellular defense: a study on patients with lower-risk MDS
About this item
Full title
Author / Creator
Kaisrlikova, Monika , Vesela, Jitka , Kundrat, David , Votavova, Hana , Dostalova Merkerova, Michaela , Krejcik, Zdenek , Divoky, Vladimir , Jedlicka, Marek , Fric, Jan , Klema, Jiri , Mikulenkova, Dana , Stastna Markova, Marketa , Lauermannova, Marie , Mertova, Jolana , Soukupova Maaloufova, Jacqueline , Jonasova, Anna , Cermak, Jaroslav and Belickova, Monika
Publisher
London: Nature Publishing Group UK
Journal title
Language
English
Formats
Publication information
Publisher
London: Nature Publishing Group UK
Subjects
More information
Scope and Contents
Contents
Patients with lower-risk myelodysplastic syndromes (LR-MDS) have a generally favorable prognosis; however, a small proportion of cases progress rapidly. This study aimed to define molecular biomarkers predictive of LR-MDS progression and to uncover cellular pathways contributing to malignant transformation. The mutational landscape was analyzed in...
Alternative Titles
Full title
RUNX1 mutations contribute to the progression of MDS due to disruption of antitumor cellular defense: a study on patients with lower-risk MDS
Authors, Artists and Contributors
Author / Creator
Vesela, Jitka
Kundrat, David
Votavova, Hana
Dostalova Merkerova, Michaela
Krejcik, Zdenek
Divoky, Vladimir
Jedlicka, Marek
Fric, Jan
Klema, Jiri
Mikulenkova, Dana
Stastna Markova, Marketa
Lauermannova, Marie
Mertova, Jolana
Soukupova Maaloufova, Jacqueline
Jonasova, Anna
Cermak, Jaroslav
Belickova, Monika
Identifiers
Primary Identifiers
Record Identifier
TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_9252911
Permalink
https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_9252911
Other Identifiers
ISSN
0887-6924
E-ISSN
1476-5551
DOI
10.1038/s41375-022-01584-3
